These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28012273)

  • 21. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pain and bleeding pattern related to levonorgestrel intrauterine system (LNG-IUS) insertion.
    Van Schoubroeck D; Van den Bosch T; Ameye L; Veldman J; Hindryckx A; Werbrouck E; Timmerman D
    Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):154-6. PubMed ID: 24029596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predicting menstrual bleeding patterns with levonorgestrel-releasing intrauterine systems.
    Frenz AK; Ahlers C; Beckert V; Gerlinger C; Friede T
    Eur J Contracept Reprod Health Care; 2021 Feb; 26(1):48-57. PubMed ID: 33269954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Application of levonorgestrel-releasing intrauterine system in early pregnancy: a case report].
    Gardyszewska A; Czajkowski K
    Ginekol Pol; 2012 Dec; 83(12):950-2. PubMed ID: 23488301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study.
    Heikinheimo O; Inki P; Schmelter T; Gemzell-Danielsson K
    Hum Reprod; 2014 Jun; 29(6):1182-8. PubMed ID: 24682613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of the levonorgestrel-releasing intrauterine system position on bleeding patterns in reproductive age women.
    Alves RDMS; Rabelo MM; Andrade VR; Cabral RCS; Merriman JW; Brito MB
    Int J Gynaecol Obstet; 2019 Dec; 147(3):326-331. PubMed ID: 31489621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS.
    Wildemeersch D; Goldstuck ND; Jackers G
    Gynecol Endocrinol; 2017 Mar; 33(3):223-226. PubMed ID: 28084114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomised trial comparing the levonorgestrel intrauterine system and thermal balloon ablation for heavy menstrual bleeding.
    Busfield RA; Farquhar CM; Sowter MC; Lethaby A; Sprecher M; Yu Y; Sadler LC; Brown P; Johnson N
    BJOG; 2006 Mar; 113(3):257-63. PubMed ID: 16487195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
    Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts.
    Reid PC; Virtanen-Kari S
    BJOG; 2005 Aug; 112(8):1121-5. PubMed ID: 16045528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of levonorgestrel-releasing intrauterine system on pain and recurrence associated with endometriosis and adenomyosis].
    Deng S; Lang JH; Leng JH; Liu ZF; Sun DW; Zhu L
    Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):664-8. PubMed ID: 17199919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
    Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
    Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of a 52-mg levonorgestrel-releasing intrauterine system in women with cardiovascular disease.
    Ueda Y; Kamiya CA; Horiuchi C; Miyoshi T; Hazama R; Tsuritani M; Iwanaga N; Neki R; Ikeda T; Yoshimatsu J
    J Obstet Gynaecol Res; 2019 Feb; 45(2):382-388. PubMed ID: 30259601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
    de Jonge ET; Yigit R; Molenberghs G; Straetmans D; Ombelet W
    Contraception; 2007 Aug; 76(2):91-5. PubMed ID: 17656176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.
    Carvalho N; Margatho D; Cursino K; Benetti-Pinto CL; Bahamondes L
    Fertil Steril; 2018 Nov; 110(6):1129-1136. PubMed ID: 30396557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
    Selim MF; Hussein AF
    Contraception; 2013 Apr; 87(4):396-403. PubMed ID: 23332246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
    Gemzell-Danielsson K; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Nelson A
    PLoS One; 2015; 10(9):e0135309. PubMed ID: 26378938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg.
    Teunissen AM; Merry AHH; Devies IEC; Roumen FJME
    Eur J Contracept Reprod Health Care; 2019 Dec; 24(6):449-456. PubMed ID: 31696740
    [No Abstract]   [Full Text] [Related]  

  • 40. Pain scores at the insertion of the 52 MG levonorgestrel-releasing intrauterine system among nulligravidas and parous women.
    Chaves IA; Baêta T; Dolabella GB; Barbosa LR; Almeida NM; Oliveira FR; Oliveira EC; L Silva-Filho A; Rocha ALL
    Eur J Contracept Reprod Health Care; 2021 Oct; 26(5):399-403. PubMed ID: 34096433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.